{"name":"Acologix, Inc.","slug":"acologix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nalfurafine HCl 2.5 µg","genericName":"Nalfurafine HCl 2.5 µg","slug":"nalfurafine-hcl-2-5-g","indication":"Chronic pruritus associated with chronic kidney disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Nalfurafine HCl 5.0 µg","genericName":"Nalfurafine HCl 5.0 µg","slug":"nalfurafine-hcl-5-0-g","indication":"Chronic pruritus in patients with end-stage renal disease on hemodialysis","status":"phase_3"}]}],"pipeline":[{"name":"Nalfurafine HCl 2.5 µg","genericName":"Nalfurafine HCl 2.5 µg","slug":"nalfurafine-hcl-2-5-g","phase":"phase_3","mechanism":"Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.","indications":["Chronic pruritus associated with chronic kidney disease","Pruritus associated with atopic dermatitis"],"catalyst":""},{"name":"Nalfurafine HCl 5.0 µg","genericName":"Nalfurafine HCl 5.0 µg","slug":"nalfurafine-hcl-5-0-g","phase":"phase_3","mechanism":"Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.","indications":["Chronic pruritus in patients with end-stage renal disease on hemodialysis","Pruritus associated with other chronic conditions"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}